Table 2.
Comparison of clinicopathological data
| Characteristics | Total n = 354 | Progression n = 122 | Non-progression n = 232 | t/Z/χ2 | p |
|---|---|---|---|---|---|
| Age (years) | 52.51±10.50 | 53.38±10.17 | 52.05±10.66 | -1.133 | 0.258 |
| BMI | 24.42±4.05 | 24.65±3.48 | 24.30±4.33 | -0.769 | 0.442 |
| Menopausal status | 0.751 | 0.386 | |||
| pre-menopause | 165 (46.6%) | 53 (43.4%) | 112 (48.3%) | ||
| post-menopause | 189 (53.4%) | 69 (56.6%) | 120 (51.7%) | ||
| CEA (ng/ml) | 1.78 (1.20, 2.79) | 1.90 (1.25, 3.01) | 1.74 (1.20, 2.70) | -1.328 | 0.184 |
| CA153 (U/ml) | 10.51 (7.89, 15.49) | 11.12 (8.24, 16.05) | 10.09 (7.61, 14.74) | -1.466 | 0.143 |
| Ki-67 (%) | 12.675 | < 0.001 | |||
| < 20 | 61 (17.2%) | 9 (7.4%) | 52 (22.4%) | ||
| ≥ 20 | 293 (82.8%) | 113 (92.6%) | 180 (77.6%) | ||
| Histological grade | 28.611 | < 0.001 | |||
| G1-2 | 221 (62.4%) | 53 (43.4%) | 168 (72.4%) | ||
| G3 | 133 (37.6%) | 69 (56.6%) | 64 (27.6%) | ||
| Lymph node metastasis | 27.244 | < 0.001 | |||
| Negative | 230 (65%) | 57 (46.7%) | 173 (74.6%) | ||
| Positive | 124 (35%) | 65 (53.3%) | 59 (25.4%) | ||
| Molecular subtypes | 26.277 | < 0.001 | |||
| Luminal A | 78 (22%) | 34 (27.9%) | 44 (19%) | ||
| Luminal B | 205 (57.9%) | 53 (43.4%) | 152 (65.5%) | ||
| HER2 over-expression | 35 (9.9%) | 11 (9%) | 24 (10.3%) | ||
| Triple negative | 36 (10.2%) | 24 (19.7%) | 12 (5.2%) |
Notes: BMI = Body Mass Index, CEA = Carcinoembryonic Antigen, CA153 = Carbohydrate Antigen 153, HER2 = human epidermal growth factor receptor 2.